- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04391049
Testen des Zusatzes der viralen Antikrebstherapie Telomelysin™ zur Radiochemotherapie bei Patienten mit fortgeschrittenem Speiseröhrenkrebs, die keine Kandidaten für eine Operation sind
Phase-I-Studie mit Erweiterungskohorte von OBP-301 (Telomelysin™) und endgültiger Radiochemotherapie für Patienten mit lokal fortgeschrittenem Speiseröhren- und gastroösophagealem Krebs, die keine Kandidaten für eine Operation sind
This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.
Studienübersicht
Status
Bedingungen
- Adenokarzinom des gastroösophagealen Überganges im klinischen Stadium III AJCC v8
- Nicht resezierbares Adenokarzinom des gastroösophagealen Überganges
- Postneoadjuvante Therapie Stadium III Adenokarzinom des gastroösophagealen Überganges AJCC v8
- Postneoadjuvante Therapie Stadium IIIA Gastroösophagealer Übergang Adenokarzinom AJCC v8
- Postneoadjuvante Therapie Stadium IIIB Gastroösophagealer Übergang Adenokarzinom AJCC v8
- Ösophagus-Adenokarzinom im klinischen Stadium II AJCC v8
- Ösophagus-Adenokarzinom im klinischen Stadium IIA AJCC v8
- Ösophagus-Adenokarzinom im klinischen Stadium III AJCC v8
- Pathologisches Stadium II Ösophagus-Adenokarzinom AJCC v8
- Pathologisches Stadium IIA Ösophagus-Adenokarzinom AJCC v8
- Pathologisches Stadium IIB Ösophagus-Adenokarzinom AJCC v8
- Pathologisches Stadium III Adenokarzinom des Ösophagus AJCC v8
- Pathologisches Stadium IIIA Adenokarzinom des Ösophagus AJCC v8
- Pathologisches Stadium IIIB Adenokarzinom des Ösophagus AJCC v8
- Plattenepithelkarzinom
- Adenokarzinom des gastroösophagealen Überganges im klinischen Stadium II AJCC v8
- Ösophagus-Adenokarzinom im klinischen Stadium IIB AJCC v8
- Fortgeschrittenes Adenokarzinom des gastroösophagealen Überganges
- Plattenepithelkarzinom
- Pathologisches Adenokarzinom des gastroösophagealen Überganges im Stadium III AJCC v8
- Pathologisches Adenokarzinom des gastroösophagealen Überganges im Stadium IIIA AJCC v8
- Pathologisches Adenokarzinom des gastroösophagealen Überganges im Stadium IIIB AJCC v8
- Postneoadjuvante Therapie Ösophagus-Adenokarzinom im Stadium III AJCC v8
- Postneoadjuvante Therapie Ösophagus-Adenokarzinom im Stadium IIIA AJCC v8
- Postneoadjuvante Therapie Ösophagus-Adenokarzinom im Stadium IIIB AJCC v8
- Adenokarzinom des gastroösophagealen Überganges im klinischen Stadium IIA AJCC v8
- Adenokarzinom des gastroösophagealen Überganges im klinischen Stadium IIB AJCC v8
- Pathologisches Adenokarzinom des gastroösophagealen Überganges im Stadium II AJCC v8
- Pathologisches Adenokarzinom des gastroösophagealen Überganges im Stadium IIA AJCC v8
- Pathologisches Adenokarzinom des gastroösophagealen Überganges im Stadium IIB AJCC v8
- Fortgeschrittenes Adenokarzinom des Ösophagus
- Postneoadjuvante Therapie Stadium II Adenokarzinom des Ösophagus AJCC v8
- Postneoadjuvante Therapie Stadium II Adenokarzinom des gastroösophagealen Überganges AJCC v8
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To determine if the addition of OBP-301 to chemoradiation with carboplatin/paclitaxel is safe.
SECONDARY OBJECTIVES:
I. To assess toxicities associated with the addition of OBP-301 to chemoradiation.
II. To assess the number of clinical complete responses (cCR).
III. To assess the number of patients alive/without progression (progression-free survival [PFS]) and the number of patients alive (overall survival [OS]) at 1 and 2 years.
EXPLORATORY OBJECTIVE:
I. To report correlate outcomes - cCR, PFS and OS - with immune and virus-based correlative assays.
OUTLINE:
This study will evaluate an initial dose of OBP-301 and a de-escalated dose, if needed.
Patients receive OBP-301 by intratumoral injection via endoscopy on days -3, 12, and 26. Patients also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 and 6-8 weeks, then every 3 months for 2 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- City of Hope Comprehensive Cancer Center
-
South Pasadena, California, Vereinigte Staaten, 91030
- City of Hope South Pasadena
-
Upland, California, Vereinigte Staaten, 91786
- City of Hope Upland
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- Moffitt Cancer Center
-
-
Kansas
-
Fairway, Kansas, Vereinigte Staaten, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- University of Kansas Cancer Center
-
Westwood, Kansas, Vereinigte Staaten, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Vereinigte Staaten, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Vereinigte Staaten, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Vereinigte Staaten, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, Vereinigte Staaten, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Vereinigte Staaten, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Vereinigte Staaten, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- UT MD Anderson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) within 90 days prior to registration
- Gastroesophageal junction tumors must be Siewert type I/II
-
Required diagnostic workup for study entry:
- History/physical examination prior to registration
- Computed tomography (CT) of the chest/abdomen with intravenous contrast within 28 days prior to registration; If CT contrast is contraindicated magnetic resonance imaging (MRI) of the chest/abdomen without contrast is permitted
- Bronchoscopy for squamous cell carcinoma (SCC) tumors that are adjacent to the airway to exclude a tracheoesophageal fistula within 42 days prior to registration
- Endoscopic ultrasound (if technically feasible) within 90 days prior to registration
- Whole body positron emission tomography (PET)/CT scan within 42 days prior to registration: Note: scan will be used for radiation treatment planning, in addition to ruling out metastatic disease
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration
-
Adequate hematologic function within 14 days prior to registration defined as follows Absolute neutrophil count ≥ 1,500/mcL (within 14 days prior to registration) Hemoglobin ≥ 9 gm/dL (within 14 days prior to registration) Platelets ≥ 100,000/mcL (within 14 days prior to registration)
-
Adequate renal function within 14 days prior to registration defined as follows Creatinine clearance of ≥ 50 ml/min (as calculated by Cockcroft-Gault equation) (within 14 days prior to registration)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)
-
AST/ALT ≤ 2.5 x ULN
-
Patients for whom non-operative management is a viable option in the opinion of a thoracic surgeon and/or multidisciplinary team and are candidates for chemoradiation; this does not preclude patients from receiving surgery after chemoradiation if felt to me medically indicated;
-
Patients must, in the opinion of a treating gastroenterologist, have a tumor that is amenable to intratumoral injection with at least 1 mL (1 x 10^12 vp/mL) of OBP-301 and be a candidate for 3 endoscopy procedures
-
Female patients of child bearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months
-
Patients of reproductive potential must agree to use effective contraception for the duration of study treatment as well as 6 months (for women) or 12 months (for men) after the last administered injection of OBP-301. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device
-
The patient must provide study-specific informed consent prior to study entry
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Known acute or chronic hepatitis B or C infection (testing not required prior to study entry in patients with no known history of hepatitis B or C)
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- For patients with a history of hepatitis C virus (HCV) infection, they must (i) have been treated and cured, (ii) for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to study entry are eligible for this trial
Exclusion Criteria:
-
Definitive clinical or radiologic evidence of metastatic disease including:
- Positive malignant cytology of the pleura, pericardium or peritoneum
- Radiographic evidence of involvement of any adjacent mediastinal structure, e.g. aorta, trachea, which would increase the risk of repeated endoscopic interventions
- Tracheoesophageal fistula
- Radiographic evidence of distant organ involvement
- Non-regional lymph nodes that cannot be contained within a radiation field
-
More than 1 esophageal lesion
-
Prior systemic chemotherapy for the study cancer
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Biopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula or recurrent laryngeal or phrenic nerve paralysis
-
For patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, a New York Heart Association functional classification 2C or worse
-
Uncontrolled diabetes
-
Infection requiring IV antibiotics at the time of registration
-
Patients requiring immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20 mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers within 7 days prior to study entry
-
Received live vaccine within 30 days prior to registration
-
Received a blood transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF), and/or oxygen supplementation within 7 days before the screening lab
-
Breast feeding females
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Treatment (OBP-301, carboplatin, paclitaxel, radiation)
Patients receive OBP-301 (1×10^12 vp/mL) by intra-tumoral injection via endoscopy on days -3, 12, and 26. Patients also receive paclitaxel IV (50 mg/m^2) over 60 minutes followed by carboplatin IV (AUC 2) over 30 minutes and on days 1, 8, 15, 22, and 29, and undergo radiation therapy (1.8 Gy/faction) on Monday through Friday beginning day 1 for 28 fractions (50.4 Gy total) over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity. |
Intravenously (IV)
Andere Namen:
Intravenously (IV)
Andere Namen:
Daily fractions
Andere Namen:
Intra-tumoral injection
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants Experiencing Any Dose-Limiting Toxicities (DLTs)
Zeitfenster: From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. A DLT is defined as the following that are definitely or probably attributed to OBP-301:
If 0 or 1 participants of 6 participants experienced a DLT, then the treatment regimen would be considered safe (and 9 more would be accrued for secondary endpoints). Otherwise, the regimen would be deemed too toxic and a second cohort of six participants would be accrued to a lower dose of OBP-301 (1 x 10^11 vp/mL). |
From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anzahl der lebendigen Teilnehmer nach 1 und 2 Jahren
Zeitfenster: Bei 1 und 2 Jahren
|
Bei 1 und 2 Jahren
|
|
|
Number of Participants by Highest Grade Adverse Event Reported
Zeitfenster: From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
|
Number of Participants With Clinical Complete Response (cCR)
Zeitfenster: 6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
Clinical complete response is defined as grossly free of disease as determined by a visual inspection or if the visual inspection was not certain, then a negative biopsy. The number of participants is determined for two populations:
|
6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
|
Number of Participants Alive Without Progression at 1 and 2 Years
Zeitfenster: At 1 and 2 years
|
Progression is defined as pathologically confirmed recurrence of local disease or clinical evidence of distant disease. |
At 1 and 2 years
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Geoffrey Y Ku, NRG Oncology
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Karzinom
- Karzinom, Plattenepithel
- Neubildungen, Plattenepithelzellen
- Organische Chemikalien
- Therapeutika
- Kohlenwasserstoffe
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Physikalische Phänomene
- Koordinationskomplexe
- Taxoid
- Cyclodececane
- Diterpene
- Gesundheitsökonomie und Organisationen
- Wirtschaft
- Carboplatin
- Paclitaxel
- Strahlentherapie
- Strahlung
- Steuern
Andere Studien-ID-Nummern
- NRG-GI007
- U10CA180868 (US NIH Stipendium/Vertrag)
- NRG-GI007 (Andere Kennung: CTEP)
- NCI-2020-02320 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- NRG-GI007 (Andere Kennung: NRG Oncology)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .